87 related articles for article (PubMed ID: 19287955)
1. Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas.
Charpin C; Giusiano S; Secq V; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
Int J Oncol; 2009 Apr; 34(4):983-93. PubMed ID: 19287955
[TBL] [Abstract][Full Text] [Related]
2. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays.
Charpin C; Secq V; Giusiano S; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
Int J Cancer; 2009 May; 124(9):2124-34. PubMed ID: 19142869
[TBL] [Abstract][Full Text] [Related]
3. [Early breast carcinoma profiling based on quantitative immunocytochemistry can help predict the risk of early distant metastasis].
Taranger-Charpin C; Giusiano S; Secq V; Djemli A; Andrac L; Lavaut MN; Allasia C; Garcia S
Bull Acad Natl Med; 2009 Dec; 193(9):2045-60; discussion 2060-1. PubMed ID: 20666017
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk.
Giusiano S; Secq V; Carcopino X; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Iovanna JL; Garcia S; Boubli L; Birnbaum D; Charpin C
Int J Oncol; 2010 Apr; 36(4):889-98. PubMed ID: 20198333
[TBL] [Abstract][Full Text] [Related]
5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
6. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
[TBL] [Abstract][Full Text] [Related]
7. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Reyes C; Jorda M; Gomez-Fernández C
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
[TBL] [Abstract][Full Text] [Related]
8. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
12. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
13. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
14. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia.
Kallel I; Khabir A; Boujelbene N; Abdennadher R; Daoud J; Frikha M; Aifa S; Sallemi-Boudawara T; Rebaï A
J Recept Signal Transduct Res; 2012 Jun; 32(3):142-9. PubMed ID: 22394363
[TBL] [Abstract][Full Text] [Related]
15. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study.
Sousa B; Paredes J; Milanezi F; Lopes N; Martins D; Dufloth R; Vieira D; Albergaria A; Veronese L; Carneiro V; Carvalho S; Costa JL; Zeferino L; Schmitt F
Histol Histopathol; 2010 Aug; 25(8):963-74. PubMed ID: 20552547
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays.
Giusiano S; Cochet C; Filhol O; Duchemin-Pelletier E; Secq V; Bonnier P; Carcopino X; Boubli L; Birnbaum D; Garcia S; Iovanna J; Charpin C
Eur J Cancer; 2011 Mar; 47(5):792-801. PubMed ID: 21194925
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma.
Ortiz-Martínez F; Sanmartín E; Pomares-Navarro E; Pérez-Balaguer A; Andrés L; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Am J Clin Pathol; 2015 Jun; 143(6):812-22. PubMed ID: 25972323
[TBL] [Abstract][Full Text] [Related]
19. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
